your market intelligence analyst
Search Results
740 results
Your search is now limited to «HIV/AIDS» expert search. 08/05/2020 12:15
More from 08/05/2020 07:22
Despite advances in treatment and remarkable improvements in cure rates, very few persons with chronic HCV infection are receiving this treatment, especially among people who use drugs, who are also disproportionately HIV-infected and incarcerated.
More from
Benzinga 08/03/2020 11:03
Merck & Co., Inc’s (NYSE: ) internal pipeline seems underappreciated by the market, and the loss of exclusivity of its cancer immunology drug Keytruda appears priced in, ...
More from Benzinga:
EurekAlert 08/03/2020
These collaborative efforts allow for data sharing and obtaining perspectives that provide additional insights into and solutions for the issues, as well as novel and innovative approaches to HIV care and treatment, for advancing the national effort to end the HIV epidemic.
More from EurekAlert:
HIV disclosure status, co-medication with ART, the occurrence of side effects on an initial regimen, low baseline CD4 count, ambulatory and bedridden baseline functional status were found to be predictors.
More from International Journal of COPD:
AIDS Research & Therapy 07/31/2020 20:00
Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies.
More from AIDS Research & Therapy:
Each jurisdiction will develop specific plans for reducing disparities in HIV prevention, transmission and treatment that will be critical to end HIV in the United States by 2030.
More from Centers for Disease Control & Prevention - HIV/AIDS Prevention (CDC):
European Respiratory Journal 07/30/2020 10:01
Purpose. HIV infection is an exclusion criterion in lung cancer trials. This multicenter phase II trial aimed to assess feasibility, efficacy and safety of first-line carboplatin plus pemetrexed (CaP) followed by pemetrexed ℗ maintenance in people living with HIV (PLHIV) with advanced non-squamous non-small cell lung cancer (NS-NSCLC). Methods. Four cycles of CaP were followed by P-maintenance therapy in patients with Eastern Cooperative Oncology Group performance status (PS) ≤2. The primary objective was a disease control rate (DCR) ≥30% after 12 weeks. Results. Of the 61 PLHIV enrolled 49 (80%) had a PS 0–1, 19 (31%) brain metastases. Median CD4 lymphocyte count was 418 cells·µL –1 (range: 18–1230), median CD4 lymphocyte nadir 169.5 cells·µL.
More from European Respiratory Journal:
AllAfrica News (Africa) 07/30/2020 07:54
However, following the medical breakthrough, which prevents the transmission of HIV and stops the virus progressing into AIDS, life expectancy of sufferers has increased dramatically.
More from AllAfrica News (Africa):
FeedNavigator (EU) 07/30/2020 06:04
Although retroviral therapy (ART) has changed the HIV infection from a fatal event to a chronic disease, treated HIV patients demonstrate high prevalence of HIV associated comorbidities including cardio/cerebrovascular diseases.
More from FeedNavigator (EU): 07/29/2020 10:29
HIV, TB, and malaria deaths could increase in low- and middle-income countries.
More from
Human medicines European public assessment report (EPAR): Tybost, cobicistat, HIV Infections, Date of authorisation: 19/09/2013, Revision: 13, Status: Authorised.
More from European Medicines Agency - EMEA (EU):

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications